Literature DB >> 19119703

Assessing the value of disease management: impact of 2 disease management strategies in an underserved asthma population.

Autumn Dawn Galbreath1, Brad Smith, Pamela R Wood, Stephen Inscore, Emma Forkner, Marilu Vazquez, Andre Fallot, Robert Ellis, Jay I Peters.   

Abstract

BACKGROUND: The goal of disease management (DM) is to improve health outcomes and reduce cost through decreasing health care utilization. Although some studies have shown that DM improves asthma outcomes, these interventions have not been examined in a large randomized controlled trial.
OBJECTIVE: To compare the effectiveness of 2 previously successful DM programs with that of traditional care.
METHODS: Nine hundred two individuals with asthma (429 adults; 473 children) were randomly assigned to telephonic DM, augmented DM (ADM; DM plus in-home visits by a respiratory therapist), or traditional care. Data were collected at enrollment and at 6 and 12 months. Primary outcomes were time to first asthma-related event, quality of life (QOL), and rates of asthma-related health care utilization. Secondary outcomes included rate of controller medication initiation, number of oral corticosteroid bursts, asthma symptom scores, and number of school days missed.
RESULTS: There were no significant differences between groups in time to first asthma-related event or health care utilization. Adult participants in the ADM group had greater improvement in QOL (P = .04) and a decrease in asthma symptoms (P = .001) compared with other groups. Of children not receiving controller medications at enrollment (13%), those in the intervention groups were more likely to have controller medications initiated than the control group (P = .01). Otherwise, there were no differences in outcomes.
CONCLUSIONS: Overall, participation in asthma DM did not result in significant differences in utilization or clinical outcomes. The only significant impact was a higher rate of controllermedication initiation in children and improvement in asthma symptoms and QOL in adults who received ADM.

Entities:  

Mesh:

Year:  2008        PMID: 19119703     DOI: 10.1016/S1081-1206(10)60222-0

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

Review 1.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  Bhupendrasinh F Chauhan; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Policy and system change and community coalitions: outcomes from allies against asthma.

Authors:  Noreen M Clark; Laurie Lachance; Linda Jo Doctor; Lisa Gilmore; Cindy Kelly; James Krieger; Marielena Lara; John Meurer; Amy Friedman Milanovich; Elisa Nicholas; Michael Rosenthal; Shelley C Stoll; Margaret Wilkin
Journal:  Am J Public Health       Date:  2010-03-18       Impact factor: 9.308

Review 3.  Interventions to improve outcomes for minority adults with asthma: a systematic review.

Authors:  Valerie G Press; Andrea A Pappalardo; Walter D Conwell; Amber T Pincavage; Meryl H Prochaska; Vineet M Arora
Journal:  J Gen Intern Med       Date:  2012-08       Impact factor: 5.128

Review 4.  Home-based educational interventions for children with asthma.

Authors:  Emma J Welsh; Maryam Hasan; Patricia Li
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 5.  Adding non-randomised studies to a Cochrane review brings complementary information for healthcare stakeholders: an augmented systematic review and meta-analysis.

Authors:  Chantal Arditi; Bernard Burnand; Isabelle Peytremann-Bridevaux
Journal:  BMC Health Serv Res       Date:  2016-10-21       Impact factor: 2.655

6.  Effect of an Education Programme for South Asians with Asthma and Their Clinicians: A Cluster Randomised Controlled Trial (OEDIPUS).

Authors:  Chris Griffiths; Stephen Bremner; Kamrul Islam; Ratna Sohanpal; Debi-Lee Vidal; Carolyn Dawson; Gillian Foster; Jean Ramsay; Gene Feder; Stephanie Taylor; Neil Barnes; Aklak Choudhury; Geoff Packe; Elizabeth Bayliss; Duncan Trathen; Philip Moss; Viv Cook; Anna Eleri Livingstone; Sandra Eldridge
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.